Aetna modified CPB 0987 for Cabenuva (cabotegravir and rilpivirine), effective September 26, 2025. Here's what billing teams need to know before submitting claims under J0741.
Aetna, a CVS Health company, updated its Cabenuva coverage policy under CPB 0987 to clarify the medical necessity criteria for both initial approval and continuation of therapy. The policy covers long-acting injectable cabotegravir and rilpivirine for HIV-1 treatment, billed primarily under HCPCS J0741, with administration reported under CPT 96372. If your practice manages HIV patients on injectable antiretroviral therapy, this policy change directly affects your prior authorization workflow and your ability to get claims paid on the first submission.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Cabotegravir and Rilpivirine (Cabenuva) |
| Policy Code | CPB 0987 Aetna |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Infectious Disease, HIV Medicine, Internal Medicine, OB/GYN (HIV-complicating pregnancy) |
| Key Action | Update prior authorization templates to reflect both approval pathways — suppressed and viremic patients — before submitting new Cabenuva starts |
Aetna Cabenuva Coverage Criteria and Medical Necessity Requirements 2025
The Aetna Cabenuva coverage policy now defines two distinct pathways to initial approval. Understanding which pathway applies to your patient is the difference between clean claims and denials.
Pathway 1: Virologically Suppressed Patients
This is the standard pathway. The member must meet all four of these criteria:
| # | Covered Indication |
|---|---|
| 1 | Currently receiving a stable antiretroviral regimen |
| 2 | Virologically suppressed with HIV-1 RNA (viral load) below 50 copies/mL |
| 3 | No history of treatment failure |
| 4 | No known or suspected resistance to cabotegravir or rilpivirine |
This pathway is straightforward for most HIV practices. If your patient is stable and suppressed on oral ART, Cabenuva is a reasonable next step, and Aetna's coverage policy reflects that. Your prior authorization request needs lab documentation — specifically viral load results from CPT 87536 (HIV-1 quantification) — showing the member is below 50 copies/mL. Don't submit without that lab data attached.
Pathway 2: Viremic Patients with High Disease Risk
This is the more complex pathway, and it's where most prior auth denials will originate. The member must meet all five of these criteria:
| # | Covered Indication |
|---|---|
| 1 | Active viremia (elevated HIV-1 RNA/viral load) |
| 2 | High risk of disease progression — specifically a CD4 count below 200 cells/microliter, or a history of AIDS-defining complications |
| 3 | Unable to achieve or maintain virologic suppression on oral ART despite intensive adherence support |
| 4 | Prescriber attestation that the patient was counseled on resistance risks to NNRTIs and INSTIs if virologic failure occurs on Cabenuva |
| 5 | No known or suspected resistance to cabotegravir or rilpivirine |
This second pathway is an expansion worth noting. Aetna is explicitly allowing Cabenuva for patients who haven't been suppressed on oral therapy — but the bar is high. "Intensive medication adherence support" needs to be documented. The prescriber attestation about resistance counseling is a hard requirement, not a soft one. If that attestation isn't in the chart and in the prior auth submission, expect a denial.
Genotype resistance testing, billed under CPT 87901 (HIV-1 reverse transcriptase and protease genotype analysis), is your documentation anchor for the "no known resistance" criterion. Pull that result and include it in the prior auth packet for either pathway.
Continuation of Therapy
Aetna covers continued Cabenuva therapy as long as the member has not experienced virologic failure. Aetna defines failure as two consecutive plasma HIV-1 RNA levels at or above 200 copies/mL. This is a specific, quantitative threshold — not clinical judgment. Your monitoring labs, again billed under CPT 87536, determine whether ongoing coverage holds. Build that into your care coordination workflow.
Aetna Cabenuva Exclusions and Non-Covered Indications
Aetna considers all uses of Cabenuva outside the two criteria sets above to be experimental, investigational, or unproven. There's no ambiguity here. If the member doesn't meet either pathway, the claim won't pay.
The policy doesn't carve out exceptions for off-label dosing schedules or patient populations not listed. Adolescents under 12 or patients weighing less than 35 kg are not covered under this policy — the FDA-approved indication limits Cabenuva to patients 12 years and older weighing at least 35 kg, and Aetna follows that boundary.
Any experimental or investigational use submitted under J0741 will generate a claim denial. Don't attempt to route off-label Cabenuva use through this policy. If you have a patient situation that doesn't clearly fit, loop in your compliance officer before billing.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HIV-1, virologically suppressed on stable ART, viral load < 50 copies/mL, no resistance | Covered | J0741, B20, Z21 | All four criteria must be met; prior auth required |
| HIV-1, active viremia, high disease risk (CD4 < 200 or AIDS-defining illness), failed oral ART adherence, prescriber attestation, no resistance | Covered | J0741, B20 | All five criteria must be met; prescriber attestation is a hard requirement |
| HIV-1 complicating pregnancy | Covered (if criteria met) | J0741, O98.711–O98.719, O98.72, O98.73 | Apply same medical necessity criteria; confirm plan-level coverage for pregnancy indications |
| Asymptomatic HIV (Z21) | Covered only with suppression pathway | J0741, Z21 | Must still meet all four suppression criteria |
| Continuation of therapy, no virologic failure | Covered | J0741, B20 | Failure defined as two consecutive viral loads ≥ 200 copies/mL |
| Virologic failure (two consecutive viral loads ≥ 200 copies/mL) | Not Covered | — | Coverage ends; switch regimen required |
| All other indications not listed above | Experimental / Not Covered | — | Will generate claim denial |
Aetna Cabenuva Billing Guidelines and Action Items 2025
The effective date of September 26, 2025 has passed. If your practice has active Cabenuva patients on Aetna plans — or plans to start new patients — act now.
| # | Action Item |
|---|---|
| 1 | Audit your active Cabenuva prior authorizations against both pathways. Identify which pathway each current patient falls under. Suppressed patients need viral load documentation below 50 copies/mL from CPT 87536. Viremic patients need adherence support documentation plus the prescriber resistance counseling attestation. Missing documentation is the most common denial driver on this drug. |
| 2 | Update your prior authorization templates to include the prescriber attestation for viremic patients. This is new and non-negotiable under the updated policy. Build an attestation field into your PA template so prescribers don't miss it. A PA submitted without that attestation for a viremic patient will be denied. |
| 3 | Confirm resistance testing is on file before submitting any new PA. CPT 87901 (HIV-1 genotype analysis) covers the resistance testing Aetna requires. If your patient hasn't had recent genotype testing, order it before submitting the PA. "No known resistance" is a criterion — you need the data to support it. |
| 4 | Bill CPT 96372 for each injection administration visit. Cabenuva requires intramuscular injection by a healthcare professional. That administration should be billed under CPT 96372 at every visit. Confirm your charge capture includes this code alongside J0741 for every Cabenuva encounter. |
| 5 | Set up viral load monitoring to protect continuation coverage. Cabenuva billing guidelines require that continuation be supported by absence of virologic failure. Two consecutive viral loads at or above 200 copies/mL ends coverage. Build monitoring labs (CPT 87536) into the care plan at regular intervals so you catch a trend before Aetna does — and before coverage lapses mid-course. |
| 6 | Flag pregnancy-complicating HIV cases for separate coverage review. The policy lists ICD-10 codes O98.711 through O98.73 as applicable. But coverage for Cabenuva in pregnancy depends on the member meeting the standard criteria and on plan-level design. Don't assume pregnancy cases auto-qualify. Confirm with the plan before initiating therapy. |
| 7 | Check plan-level exclusions. CPB 0987 sets the baseline Aetna Cabenuva coverage policy, but individual employer plans can restrict coverage further. Before starting any new patient on Cabenuva, verify the specific plan doesn't exclude the drug or require step therapy. A plan exclusion overrides the CPB — and you won't see it in the policy document. |
If you're managing a large HIV panel with mixed Aetna plan types, talk to your billing consultant before the end of Q4 2025 to identify any at-risk claims.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cabenuva Under CPB 0987
HCPCS Codes Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J0741 | HCPCS | Injection, cabotegravir and rilpivirine, 2mg/3mg |
Supporting CPT Codes Related to CPB 0987
| Code | Type | Description |
|---|---|---|
| 87536 | CPT | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification (viral load) |
| 87901 | CPT | Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease |
| 96372 | CPT | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| B20 | Human immunodeficiency virus [HIV] disease |
| O98.711 | Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIV] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIV] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIV] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status |
One note on Cabenuva billing reimbursement: J0741 is a per-unit code — 2mg cabotegravir/3mg rilpivirine per unit. Given the doses involved (400–600 mg cabotegravir and 600–900 mg rilpivirine per injection), your unit calculation matters. An incorrect unit count on J0741 is a fast path to a partial payment or claim denial. Confirm your billing team knows the conversion before the first claim goes out.
Get the Full Picture for CPT 96372
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.